Multiple Sclerosis Management: Shedding Light on the Patient Perspective (Credit Expired)
This activity, originally held as a satellite symposium in conjunction with the 2021 Consortium of Multiple Sclerosis (MS) Centers (CMSC) Annual Meeting, is designed to contextualize contemporary management approaches through the documented experiences of people with MS. Drs Benjamin Greenberg, Jennifer Graves, and Anthony Traboulsee present data from a large cohort of patients illustrating their perspectives on a variety of management issues related to their care. Combined with published research on these topics, the patient data provide a platform for a unique and multidimensional scientific discussion that both navigates prevalent and illuminates under-recognized considerations in the long-term management of MS.
The target audience for this initiative includes MS specialists, general neurologists, nurse practitioners, physician assistants and other healthcare professionals involved in the diagnosis and long-term management of patients with MS.
Upon completion of the educational activity, participants should be able to:
- Identify concerns, misconceptions, and preferences of patients with MS surrounding their experience with disease management, and explore strategies to enhance and/or tailor counseling practices, communication, and treatment approach.
- Appraise key indicators for MS risk stratification to improve strategic decision-making in treatment initiation and subsequent long-term outcomes for patients who present with varying disease presentations.
- Describe expert perspectives regarding the optimal approach to monitoring disability progression and therapeutic response as well as managing breakthrough disease in patients with MS, including the indications for disease-modifying therapy (DMT) discontinuation and/or switching, to inform these decisions in clinical practice.
Benjamin M. Greenberg, MD, MHS (Moderator & Chair)
Vice Chair of Translational Research & Strategic Initiatives
Professor, Department of Neurology & Neurotherapeutics
University of Texas Southwestern Medical Center
Jennifer Graves MD, PhD
Associate Professor of Neurosciences
UC San Diego Health
San Diego, California
Anthony Traboulsee, MD
Professor, Division of Neurology
Research Chair of the MS Society of Canada
University of British Columbia in Vancouver
Credit for this program has expired. The accreditation information below is based on the activity release date.
This activity is jointly provided by the MS Foundation, Postgraduate Institute for Medicine and Efficient LLC.
In support of improving patient care, this activity has been planned and implemented by the MS Foundation, Postgraduate Institute for Medicine (PIM) and Efficient LLC. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PIM designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Disclosure of Conflict of Interest
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planners' and Managers' Disclosure
MS Foundation planners and managers have nothing to disclose. PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.
Dr Graves reported the following financial relationships:
- Consulting Fees: Genentech
- Fees for Non-CE Services: BMS, Alexion
- Contracted Research: Biogen, EMD Serono
- Clinical Steering Committee: Novartis
Dr Greenberg reported the following financial relationships:
- Consulting Fees: Abcam, Alexion, Axon Advisors, EMD Serono, Greenwich Bio, Novartis, Roche, Rubin Anders, Seigel Rare Neuroimmune Association (unpaid), Viela Bio
- Contracted Research: CLENE Nanomedicine, The Guthy Jackson Charitable Foundation, NIH, NMSS, PCORI, SRNA, Anokion
Dr Traboulsee reported the following financial relationships:
- Consulting Fees: Roche, Genzyme, Biogen, Novartis
- Fees for Non-CE Services: Roche
- Contracted Research: Roche, Genzyme, Clene, CMSC
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by an educational grant from Genentech, A Member of the Roche Group.